Levi & Korsinsky notifies investors that it has commenced an investigation into Teva Pharmaceutical Industries Limited (NYSE: TEVA) concerning potential violations of the federal securities laws.
On July 31, 2025, Teva published a press release reporting the Company’s second quarter 2025 financial results. As part of the press release, Teva disclosed that generic product revenues were down. The Company’s management predicted a flat year for generic revenue globally, blaming the delay of certain generic launches. Following this news, Teva’s stock price fell over 8.2% to close at $15.45 per share on July 31, 2025.
If you suffered a loss on your Teva Pharmaceutical Industries Limited securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





